Will US Follow UK on Managed Biosimilar Switching of IBD Patients on Infliximab?
Biosimilars Council Wants Elimination of 6-Month Exclusivity for Biologics
FDA Accepts Mylan-Biocon Pegfilgrastim Biosimilar Application
AbbVie, Novartis Unhappy With FDA Guidance on Naming Biologics and Biosimilars
Herceptin, Rituxan Biosimilars Might Soon Reach Oncologists in Europe
Efficacy and Safety of Anti-TNF-alpha Biosimilars Comparable to Reference Drugs in RA and AS
Legal and Regulatory Decisions Likely to Drive Biosimilar Approvals in 2017
Will 2017 Change the Fate of Biosimilars? An Update From the CBI Summit
How Will Pfizer's Infliximab Biosimilar Compete With Remicade?
ECCO Supports Switching From Remicade to Biosimilar Infliximab for IBD Patients
Treating Rheumatoid Arthritis With Biologic Medications: A Quick Take
The FDA vs the EC: Two Very Different Ways to Address Biosimilar Education
What Influences Physicians' Decisions About Patient Suitability for Biosimilar Infliximab?
Three Insulin Makers Face Class-Action Lawsuit on Price Fixing
FDA Filing of Sandoz's Humira Biosimilar Delayed
Novartis: The Company at the Forefront of Biosimilar Development
EMA Committee Recommends Approval of Amgen's Adalimumab Biosimilar
Novartis's Enbrel Biosimilar Marketing Delayed
Are Biosimilars Potential Market Disruptors?
EMA Launching Pilot to Support Biosimilars Development
FDA Releases Draft Guidance on Biosimilar Interchangeability
Biosimilars for Psoriasis: Spain's Dermatologists Weigh In
FDA Extends NDA Review Period for New RA Treatment Expected to Compete with Humira
Boehringer Ingelheim Adalimumab Biosimilar Accepted for Review by FDA and EMA
Pfizer Announces Positive Trial Results for Potential Humira Biosimilar
What Lies Ahead for the Big Three RA Drugs?
Should Biosimilars Be Interchangeable with Biologics?
Interchangeability is the real question.
Biotech Movers and Shakers: Eye on Oncobiologics
We'll feature the latest biotechnolology "movers and shakers"--and how they are impacting the biosimilars industry.
Medicare Reimbursing for Inflectra, Pfizer's Infliximab Biosimilar